Tempo-Spatial Dynamics of Antimicrobial Consumption in Nigeria

Unlocking Antimicrobial Consumption Dynamics: Mapping Trends, Patterns, and Drivers for Targeted Antimicrobial Resistance (AMR) Interventions. Our innovation dives into the tempo-spatial nuances of antimicrobial consumption across Nigeria, paving the way for evidence-based strategies to safeguard public health against AMR.

Mrs Niniola Williams (Managing Director, DRASA Health Trust)

This innovation (DRASA Antimicrobial Consumption Monitoring for Antimicrobial Data - DACOMAD) addresses the lack of comprehensive antimicrobial consumption (AMC) data in rural and under-served areas of Nigeria, where access to formal healthcare is limited and these drugs are often consumed without the advice or diagnosis of a trained professional. Community pharmacies and patent medicine vendors play crucial roles in distributing antimicrobials, yet there is insufficient information on their use and misuse. This knowledge gap impedes effective antimicrobial resistance (AMR) mitigation.

The innovation aims to utilize advanced Geographic Information System (GIS) tools to map and visualize AMC patterns in both human and animal populations, considering spatial and temporal dynamics. By integrating human-related and animal-related variables, including the distribution and accessibility of antimicrobial at points of sale, the innovation seeks to provide a holistic understanding of AMC patterns. Additionally, the development of a hybrid data application (DACOMAD) will facilitate the aggregation and dissemination of up-to-date AMC information, aiding informed decision-making and optimization of healthcare services in under-reached communities. Ultimately, this tool strives to contribute valuable insights into AMC patterns in remote areas of Nigeria and inform targeted interventions to combat AMR effectively.

Our solution, the DACOMAD tool, will serve diverse stakeholders in healthcare delivery and antimicrobial stewardship in Nigeria, especially in rural and under-served areas, with data and critical information on consumption patterns. This encompasses pharmacists, physicians, veterinarians, policymakers, and regulatory authorities overseeing public health and antimicrobial resistance  (AMR) management. By providing comprehensive data on antimicrobial consumption (AMC) patterns, the tool empowers healthcare professionals to optimize prescribing practices, enhance patient education, and pinpoint areas for effective AMR interventions. Policymakers and regulators can leverage this data to formulate evidence-based policies, regulate antimicrobial distribution, and promote stewardship initiatives. Further, the community pharmacies and proprietary patent and medicine vendors will be served with a solution to strengthen their businesses and sales as the DACOMAD tool also provides vendors with key services such as management of their inventory and sales data. This ensures uptake as they directly benefit from using the tool.   

Through surveys, interviews, and consultations, we will engage stakeholders to further understand their needs and gather feedback iteratively. Collaborating with local healthcare organizations and government agencies, we will  tailor the tool to specific community contexts. This iterative approach ensures that the DACOMAD tool meets stakeholder requirements, contributing significantly to the fight against antimicrobial resistance.

The DACOMAD tool solution provides several public goods to combat antimicrobial resistance (AMR) and improve public health in Nigeria. By offering comprehensive data on antimicrobial consumption (AMC) patterns in dashboard format, DACOMAD enhances surveillance, enabling stakeholders to monitor trends, identify hotspots, and respond swiftly to emerging AMR threats. This proactive approach also informs public facing communications on AMC trends.

Furthermore, DACOMAD promotes antimicrobial stewardship by empowering healthcare professionals with evidence-based insights into prudent antimicrobial use. Through real-time updates and spatial visualizations, the tool facilitates informed decision-making, minimizing unnecessary antimicrobial usage, and reducing AMR risk.

Moreover, DACOMAD fosters transparency and accountability within the pharmaceutical sector via its vendor management system. By enabling effective sales tracking and inventory management, the tool promotes regulatory compliance and ensures the quality and safety of antimicrobial distribution, bolstering public trust in pharmaceutical services and safeguarding community health.

Overall, DACOMAD is a valuable public good advancing antimicrobial stewardship, strengthening surveillance, and promoting regulatory compliance within healthcare. By addressing these critical needs, the solution contributes significantly to protecting public health and combating the global threat of AMR.

The DACOMAD solution will create tangible impact by enhancing antimicrobial stewardship, strengthening surveillance capabilities, and promoting regulatory compliance within the healthcare sector in Nigeria. For healthcare professionals, policymakers, and regulatory authorities, the solution will empower evidence-based decision-making, optimize antimicrobial prescribing practices, and enable targeted interventions to combat antimicrobial resistance (AMR). By providing real-time insights into antimicrobial consumption (AMC) patterns, DACOMAD will facilitate the identification of hotspots and emerging threats of AMR, allowing stakeholders to respond promptly and effectively.

Moreover, the impact of DACOMAD will be particularly pronounced in rural and underserved areas of Nigeria, where access to healthcare infrastructure and resources is limited. In these regions, the solution will fill critical gaps in AMC data collection and analysis, enabling healthcare providers to better understand local AMC trends and tailor interventions to address specific challenges. Additionally, DACOMAD's vendor management system will promote transparency and accountability within community pharmacies and patent medicine vendors, ensuring the safe and responsible distribution of antimicrobials in these underserved communities. Overall, DACOMAD will create tangible impact by improving public health outcomes, mitigating AMR risks, and strengthening healthcare delivery in both urban and rural settings across Nigeria.

Over the next year, we plan to scale our impact by focusing on several key strategies. Firstly, we will prioritize expanding the reach of the DACOMAD tool to additional regions within Nigeria, particularly in rural and underserved areas where the burden of antimicrobial resistance (AMR) is often highest. This will involve engaging local healthcare facilities, community pharmacies, and patent medicine vendors to onboard them onto the platform and facilitate data collection. Additionally, we will conduct training sessions and workshops to educate stakeholders on the importance of antimicrobial stewardship and the utilization of the DACOMAD tool for informed decision-making.

Over the next three years, our scaling efforts will continue to focus on expanding the geographical coverage of the DACOMAD tool across Nigeria. We will leverage partnerships with governmental and non-governmental organizations to facilitate the adoption of the tool at a national level, ensuring widespread access to comprehensive AMC data. Furthermore, we will explore opportunities for collaboration with international organizations and research institutions to adapt the DACOMAD model for implementation in other sub-Saharan African countries (particularly West Africa) facing similar challenges with AMR. By scaling our impact both locally and internationally, we aim to contribute significantly to the global fight against AMR.

We will measure success against our impact goals through a combination of quantitative and qualitative metrics. Quantitatively, we will track key indicators such as the expansion of geographic coverage of the DACOMAD tool, the number of healthcare facilities and pharmacies onboarded onto the platform, and the volume of antimicrobial consumption data collected and analyzed. Additionally, we will monitor changes in AMC patterns over time, including reductions in inappropriate antimicrobial prescribing and dispensing practices.

Qualitatively, we will assess the impact of the DACOMAD tool on healthcare practices and policies through stakeholder feedback, case studies, and success stories. We will gather insights from healthcare professionals, policymakers, and regulatory authorities on how the tool has influenced decision-making, improved antimicrobial stewardship practices, and enhanced public health outcomes. Moreover, we will conduct regular evaluations and surveys to assess stakeholders' satisfaction with the tool's usability, functionality, and effectiveness in addressing AMR challenges.

By systematically tracking both quantitative and qualitative metrics, we will be able to gauge the effectiveness of our interventions, identify areas for improvement, and adapt our strategies accordingly to achieve our impact goals in combating antimicrobial resistance and improving public health outcomes in Nigeria.

Several barriers may hinder our goal achievement over the next one to three years. Firstly, limited access to healthcare infrastructure and resources in rural and underserved areas may impede the expansion of the DACOMAD tool's geographic coverage and the onboarding of healthcare facilities and pharmacies onto the platform. Additionally, resistance to change and a lack of awareness among stakeholders about the importance of antimicrobial stewardship and the utility of the DACOMAD tool may pose challenges to adoption and implementation.

To overcome these barriers, we plan to implement several strategies. Firstly, we will prioritize community engagement and capacity-building initiatives to raise awareness about the importance of antimicrobial stewardship and the benefits of utilizing the DACOMAD tool. This will involve conducting targeted outreach programs, training sessions, and educational workshops to empower stakeholders with the knowledge and skills needed to effectively utilize the tool.

Additionally, we will collaborate closely with local healthcare organizations, government agencies, and community leaders to address infrastructure challenges and ensure the successful implementation of the DACOMAD tool in underserved areas. By leveraging partnerships and engaging stakeholders at all levels, we aim to overcome barriers and achieve our goals of combating antimicrobial resistance and improving public health outcomes in Nigeria.

We are applying to The Trinity Challenge because it offers a unique opportunity to leverage our expertise and innovative solution, DACOMAD, in combating antimicrobial resistance (AMR). This challenge aligns with our mission to address critical global health issues and provides a platform to collaborate with diverse stakeholders and amplify our impact.

The barriers we face include limited access to healthcare infrastructure in rural and underserved areas, stakeholder resistance to change, and a lack of awareness about antimicrobial stewardship and the utility of the DACOMAD solution. The Trinity Challenge can help us overcome these barriers by providing access to resources, expertise, and partnerships to scale our solution effectively. Specifically, we aim to collaborate with The Trinity Challenge to expand the reach of DACOMAD, particularly in rural and underserved areas, where access to healthcare infrastructure is limited. We also aim to develop a real-time data dashboard to monitor antimicrobial consumption data and engage with policymakers and regulatory authorities to raise awareness about the importance of antimicrobial stewardship. Through strategic collaboration and support from The Trinity Challenge, we can address these barriers and accelerate our efforts to combat AMR and improve public health outcomes.

1. Pharmaceutical companies in Nigeria 
2. PharmAccess Foundation Nigeria
3. Technology partners (Oracle, Amazon Web Services, Health Information Technology for Economic and Clinical Health (HITECH), Google)
4. International Organizations (World Health Organization-Nigeria, Food and Agriculture Organization)